CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eli Lilly and Co is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eli Lilly and Co
Lilly Corporate Ctr, Drop Code 1094
Phone: (317) 276-2000p:317 276-2000 INDIANAPOLIS, IN  46285  United States Ticker: LLYLLY
Business Summary
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4ß7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule FXR314.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer David A.Ricks 57 6/1/2017 1/1/2012
Chief Financial Officer, Executive Vice President Lucas E.Montarce 47 9/9/2024 9/9/2024
Executive Vice President, Chief Information and Digital Officer DiogoRau 50 1/1/2022 5/17/2021
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Eli Lilly and Company (Taiwan), Inc. Taiwan, Republic of China
ELI LILLY SERVICES, INC.
ELI LILLY AND CO (IRELAND) LIMITED DUNDERROW KINSALECORK IE
53 additional Subsidiary records available in full report.

Business Names
Business Name
Akouos Inc
Akouos Securities Corporation
Akouos, Inc.
174 additional Business Names available in full report.

General Information
Number of Employees: 47,000 (As of 12/31/2024)
Outstanding Shares: 947,989,151 (As of 2/26/2025)
Shareholders: 17,903
Stock Exchange: NYSE
Federal Tax Id: 350470950
Fax Number: (317) 276-3492


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025